Pioglitazone
CAS No. 111025-46-8
Pioglitazone( U-72107 )
Catalog No. M10411 CAS No. 111025-46-8
Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 5MG | 33 | In Stock |
|
| 10MG | 46 | In Stock |
|
| 25MG | 60 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | 133 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 327 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePioglitazone
-
NoteResearch use only, not for human use.
-
Brief DescriptionPioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
-
DescriptionPioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.(In Vitro):Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15.Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs.(In Vivo):Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle.Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.
-
In Vitro——
-
In VivoAnimal Model:ob/ob and adipo-/- ob/ob mice with a C57Bl/6 backgroundDosage:10 or 30 mg/kgAdministration:Oral gavage; once daily; 14 daysResult:Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.Animal Model:Male Wistar albino rats Dosage:10 mg/kg Administration:Oral gavage; once daily; 4 weeks Result:Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.
-
SynonymsU-72107
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPAR
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number111025-46-8
-
Formula Weight356.44
-
Molecular FormulaC19H20N2O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 15 mg/mL (42.08 mM)
-
SMILESO=C(C(S1)CC(C=C2)=CC=C2OCCC3=NC=C(CC)C=C3)[N]C1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jaakkola T, et al. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-5
molnova catalog
related products
-
Elafibranor
A nove, potent dual PPAR α/δ agonist with EC50 of 45 and 175 nM, respectively.
-
GW7647
GW7647 is a potent agonist of PPARα (EC50s: 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ, and PPARδ, respectively).GW7647 (50 nM) stimulates the PI3K phosphorylation followed by the Akt (Ser473) phosphorylation, which causes NOS1 phosphorylation increased the amounts of NO released in the stripped antral mucosa.
-
Hydroxyhexamide
Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent.
Cart
sales@molnova.com